64 results on '"Shepherd, Frances A."'
Search Results
2. Treatment patterns and outcomes in KRASG12C‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
3. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer
4. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
5. Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience
6. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
7. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer
8. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer
9. Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients
10. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
11. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases
12. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models
13. Ongoing and future trials of biologic therapies in lung cancer
14. Angiogenesis inhibitors under study for the treatment of lung cancer
15. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance
16. Second line chemotherapy for NSCLC: establishing a gold standard
17. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer
18. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
19. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
20. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
21. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
22. Uncommon EGFR mutations in advanced non-small cell lung cancer
23. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial
24. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC)
25. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
26. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)
27. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA
28. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
29. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
30. Corrigendum to: “Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer institute of Canada and intergroup trial JBR.10 and a review of the literature” [Lung Cancer 47 (2005) 385–394]
31. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?
32. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer
33. Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study
34. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer
35. O-268 Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus: Prediction and impact of pathologic complete response (CR)
36. Phase II study of pegylated liposomal doxorubicin HCI (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
37. O-201 A phase II trial of induction chemotherapy followed by extrapleural pneumonectomy and high-dose hemithoracic radiation for malignant pleural mesothelioma
38. PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy
39. O-118 Optmizing cancer treatment decision-making: Pilot study of a treatment decision aid in stage IV non-small cell lung cancer
40. O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)
41. P-253 Anemia as a prognostic factor in induction chemotherapy for stage IIIA N2 non small cell lung cancer (NSCLC)
42. O-233 Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analysis of the published literature
43. O-123 Hemithoracic radiotherapy for mesothelioma — challenges and solutions
44. Robert J. Ginsberg, MD FRCS(C), March 30, 1940–March 1, 2003
45. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
46. Angiogenesis inhibitors in the treatment of lung cancer
47. Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma
48. Paclitaxel and ifosfamide combinations for non-small cell lung cancer
49. The role of gemcitabine in the treatment of small cell lung cancer
50. Single agent gemcitabine activity in non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.